Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzymatic Reduction . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102605011B details a novel KRED102-catalyzed route for statin intermediates, offering high-purity chiral building blocks with simplified aqueous processing and reduced manufacturing costs.
Patent CN104328148A details high-purity enzymatic synthesis. Offers cost reduction and supply chain reliability for global API manufacturers.
Patent CN103695486A reveals a novel one-pot enzymatic route for Atorvastatin intermediates, offering significant cost reduction and safer manufacturing for global API producers.
Patent CN102154384A reveals efficient recombinant E. coli method yielding >26g/L with >99% ee, offering significant cost and supply chain advantages.
Patent CN101831479B reveals a microbial method for synthesizing sulforaphane precursors, offering significant cost reduction and scalable production for pharmaceutical intermediates.
Patent CN105492606A enables efficient (-)-vibo-quercitol production via novel reductase, offering high purity and cost reduction for pharma intermediates.
Patent CN109837317B details a novel enzymatic method for synthesizing high-purity chiral alcohols, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN118516426A reveals enzymatic route for chiral intermediates. High purity, mild conditions, cost-effective for pharma supply chains.
Novel membrane bioreactor method ensures high purity Ezetimibe intermediate with reduced costs and scalable production for global pharmaceutical supply chains.
Patent CN111454918A details a novel OYE3-Mut mutant for >99% ee (R)-citronellal, offering cost-effective biocatalytic solutions for flavor and pharma intermediates.
Patent CN111235123A reveals a novel carbonyl reductase enabling high-substrate loading biocatalysis, offering significant cost reduction and purity advantages for pharmaceutical manufacturing.
Novel LsCR mutant enables efficient synthesis of chiral alcohols for anticoagulants. Enhanced stability and activity reduce manufacturing costs for pharmaceutical intermediates.
Novel KRED enzyme process for ticagrelor intermediate. High selectivity, mild conditions, cost-effective supply chain solution for pharma manufacturing.
Patent CN118374465B reveals enzymatic route for (S)-nicotine. Achieves 99.1% ee value. Offers scalable biocatalysis for reliable pharmaceutical intermediates supplier chains.
Patent CN106282135A details a robust RrQR enzyme process for (R)-3-quinuclidinol, offering superior stability and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN106282134A details KgQR enzyme for high yield synthesis. Offers significant cost reduction and supply chain reliability for global pharmaceutical intermediate manufacturing partners.
Patent CN117210426A reveals enzyme mutant for chiral alcohol synthesis. Offers cost reduction in API manufacturing and reliable pharmaceutical intermediate supplier solutions.
Novel enzymatic route for Darunavir intermediate (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]furan-3-ol offering high optical purity and industrial scalability.
Advanced flow synthesis for Crizotinib intermediates reduces cost and improves supply chain reliability for pharmaceutical manufacturing partners globally seeking scalable solutions.
Patent CN114277006A reveals a novel alcohol dehydrogenase for synthesizing chiral heterocyclic alcohols without organic solvents, offering significant supply chain and cost advantages.